271 related articles for article (PubMed ID: 16835318)
1. Clinical use of p53 in Barrett's esophagus.
Keswani RN; Noffsinger A; Waxman I; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
3. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
4. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
7. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
9. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
10. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
11. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
12. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
[TBL] [Abstract][Full Text] [Related]
14. [Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis].
Fléjou JF; Volant A; Diebold MD; Sagan C; Vissuzaine C; Croué A; Robaszkiewicz M; Potet F
Gastroenterol Clin Biol; 1995 May; 19(5):475-81. PubMed ID: 7589998
[TBL] [Abstract][Full Text] [Related]
15. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
Chung SM; Kao J; Hyjek E; Chen YT
Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
[TBL] [Abstract][Full Text] [Related]
16. Barrett's esophagus: can biomarkers predict progression to malignancy?
Tischoff I; Tannapfel A
Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
[TBL] [Abstract][Full Text] [Related]
17. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
18. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus: current and future management.
Wang KK
Compr Ther; 1994; 20(1):36-43. PubMed ID: 8137618
[TBL] [Abstract][Full Text] [Related]
20. Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus.
Tsai TT; Bongiorno PF; Orringer MB; Beer DG
Cancer Detect Prev; 1997; 21(4):326-31. PubMed ID: 9232323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
